Clinical Trial Center Maastricht B.V.
- Address
- lock Available on a paid plan
Cancer (Neoplasms)
The department focuses on solid tumours of the biliary system, studying patients after curative resection of cholangiocarcinoma and muscle‑invasive gallbladder carcinoma. The aim is to test an adjuvant regimen of gemcitabine and cisplatin to improve disease‑free survival compared with observation or capecitabine alone.
- Adjuvant chemotherapy after curative surgery
- Combination of gemcitabine and cisplatin
- Disease‑free survival as primary endpoint
- Management of biliary tract cancers
Clinical Trial Center Maastricht B.V. leads this investigation, aiming to set a new standard for postoperative care in biliary malignancies.
Respiratory Tract Diseases
Research in this area targets patients with advanced non‑small cell lung carcinoma (NSCLC), exploring whether a reduced dose of pembrolizumab can achieve comparable overall survival to the standard regimen, thereby enhancing cost‑effectiveness.
- Immunotherapy dose reduction strategies
- Non‑inferiority assessment in advanced NSCLC
- Overall survival outcomes
- Economic considerations in lung cancer treatment
The site’s investigators are evaluating this approach to make life‑extending immunotherapy more accessible for lung cancer patients.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 271 other sites in The Netherlands
Therapeutic Area Benchmark — The Netherlands
Select a therapeutic area to compare against other sites in The Netherlands.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: The Netherlands
Market Share
Country: The Netherlands
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Clinical Trial Center Maastricht B.V.
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy of Gemcitabine Hydrochloride and Cisplatin Versus Standard Care in Post-Resection Cholangiocarcinoma and Muscle-Invasive Gallbladder Carcinoma | University Medical Center Hamburg-Eppendorf | Phase III | Not Recruiting | Nov 2024 | Dec 2025 |
IMP list
lock Showing 1 of 4 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Capecitabine | 1 | Unknown | 2024-11-19 | 2024-11-19 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.